ArticleEuropean journal of nuclear medicine and molecular imaging2013
PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings.
Article in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.European journal of nuclear medicine and molecular imaging · 2017Trial
- Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary?Nuclear medicine communications · 2015Trial
- A Head-to-Head Comparison ofJournal of clinical medicine · 2022Article
- 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.Thoracic cancer · 2019Review
- Chest Magnetic Resonance Imaging Decreases Inter-observer Variability of Gross Target Volume for Lung Tumors.Frontiers in oncology · 2019Article
- Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.European journal of nuclear medicine and molecular imaging · 2018Article
- What Do We Measure in Oncology PET?Nuclear medicine and molecular imaging · 2017Review
- Uncertainties in target volume delineation in radiotherapy - are they relevant and what can we do about them?Radiology and oncology · 2016Article
- Use of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning for Lung Cancer.Molecular imaging and radionuclide therapy · 2016Article
- Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation.European journal of nuclear medicine and molecular imaging · 2016Article
- The Impact of Diffusion-Weighted MRI on the Definition of Gross Tumor Volume in Radiotherapy of Non-Small-Cell Lung Cancer.PloS one · 2016Article
- Application of partial volume effect correction and 4D PET in the quantification of FDG avid lung lesions.Molecular imaging and biology · 2015Article
- State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET.Frontiers in medicine · 2015Review
- FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity.European journal of nuclear medicine and molecular imaging · 2014Article
- Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities.Journal of thoracic disease · 2014Review
- Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study.European journal of nuclear medicine and molecular imaging · 2014Article
- The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer.Frontiers in oncology · 2014Review
- Volumetric CT-based segmentation of NSCLC using 3D-Slicer.Scientific reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe objective of the study was to validate an adaptive, contrast-oriented thresholding algorithm (COA) for tumour delineation in (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for non-small cell lung cancer (NSCLC) in comparison with pathological findings. The impact of tumour localization, tumour size and uptake heterogeneity on PET delineation results was also investigated.
methodsPET tumour delineation by COA was compared with both CT delineation and pathological findings in 15 patients to investigate its validity. Correlations between anatomical volume, metabolic volume and the pathology reference as well as between the corresponding maximal diameters were determined. Differences between PET delineations and pathological results were investigated with respect to tumour localization and uptake heterogeneity.
resultsThe delineated volumes and maximal diameters measured on PET and CT images significantly correlated with the pathology reference (both r > 0.95, p < 0.0001). Both PET and CT contours resulted in overestimation of the pathological volume (PET 32.5 ± 26.5%, CT 46.6 ± 27.4%). CT volumes were larger than those delineated on PET images (CT 60.6 ± 86.3 ml, PET 48.3 ± 61.7 ml). Maximal tumour diameters were similar for PET and CT (51.4 ± 19.8 mm for CT versus 53.4 ± 19.1 mm for PET), slightly overestimating the pathological reference (mean difference CT 4.3 ± 3.2 mm, PET 6.2 ± 5.1 mm). PET volumes of lung tumours located in the lower lobe were significantly different from those determined from pathology (p = 0.037), whereas no significant differences were observed for tumours located in the upper lobe (p = 0.066). Only minor correlation was found between pathological tumour size and PET heterogeneity (r = -0.24).
conclusionPET tumour delineation by COA showed a good correlation with pathological findings. Tumour localization had an influence on PET delineation results. The impact of tracer uptake heterogeneity on PET delineation should be considered carefully and individually in each patient. Altogether, PET tumour delineation by COA for NSCLC patients is feasible and reliable with the potential for routine clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.